What began as a standard mission quickly spiraled into something far more intense. Inside the cramped fuselage of a Caribou, ...

Photographer Pat Kane's multimedia Ekwǫ̀ project is based on time he spent with the Tłı̨chǫ Government’s land-based caribou ...

An error has occurred. Please try again. With a Centralmaine.com subscription, you can gift 5 articles each month. It looks like you do not have any active ...

Caribou Biosciences recently announced positive phase 1 clinical data for its allogeneic CAR-T cell therapies, vispacabtagene regedleucel (vispa-cel) for relapsed or refractory B cell non-Hodgkin ...

Caribou Biosciences (CRBU) just shared early clinical findings from its CaMMouflage phase 1 study of CB-011, an off-the-shelf CAR-T therapy for relapsed or refractory multiple myeloma. The data brings ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Caribou Coffee, the premium coffeehouse known for handcrafted beverages and real ingredients, announces its holiday lineup, launching in stores nationwide beginning Saturday, Nov. 1. This season, ...

“The big one is on the left,” my Inuit guide, Amos Irkok, said with a twinge of excitement in his soft voice. I crawled up the back side of a bald, pebble-covered hilltop toward a coffee-table-sized ...

Elisabetta Canteri does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

The beverage sector has housed some of the fastest-risers in recent years, from Dutch Bros’ race past 1,000 units to 7 Brew opening 141 net locations in a single year. At the top, Starbucks, despite ...

Caribou Biosciences’ 2025 outlook aimed for key trial readouts for two cancer cell therapies in the first half of the year and the start of clinical testing in an autoimmune disease. The CRISPR ...

Shares of Caribou Biosciences (NASDAQ:CRBU) will be in focus on Friday after the gene-editing biotech announced plans to prioritize its lead oncology clinical programs, CB-010 and CB-011, as part of a ...